Article summary
The Innovative Medicines Initiative (IMI) has published multiple initiatives in order to foster precompetitive paediatric research into therapies. The IMI believes that it is 'time to close the paediatric gap' and one of the initiatives it is currently working is the ITCC-P4, a project focused on children’s cancer medicine, which aims to 'significantly improve and accelerate science-driven new oncology drug development for children by providing high-quality biological and preclinical evidence that a particular regime would be safe for use in children with cancer'. The objective of the ITCC-P4 is to 'create a testing platform with 400 new preclinical models of high-risk paediatric solid tumours that can be used to carry out early drug testing'.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial